The trial was stopped after 67 months owing to futility on the basis of prespecified criteria, and although there was an 11% reduction in 60-day mortality in the ECMO group, this failed to reach statistical significance.
← all excerpts
Management Strategies for Severe and Refractory Acute Respiratory Distress Syndrome: Where Do We Stand in 2018?
1
—
—